The blockbuster drug Ozempic & its other GLP-1 receptor agonists counterparts, once prescribed for diabetes, is now prescribed off label for weight loss. These drugs have become so popular that we are in shortage of them in Australia. Currently, there are limited long term studies on the effects of taking this medication, which begs the question, how informed are individuals taking these drugs? In this episode we have a look at what the scientific literature says so far, as well as some of the emotional & psycho/spiritual factors at play with overweight & obesity that taking this drug bypasses.
Support my work buymeacoffee.com/angelmunro
Book in a session with me https://www.angel-munro.com/services
Watch
Who is Responsible for Four Health? Steps to Take to Keep Your Health in Your Hands.
Weight Management Beyond Diets, Calorie Counting, Macro’s & Fitness Trackers
References
Cairns, R., & Buckley, N. (2023). Semaglutide exposures reported to the NSW Poisons Information Centre: Effects of social media marketing and supply chain disruptions. Internal Medicine Journal, 53(4), 654–655. https://doi.org/10.1111/imj.16059
Davis, C., Huggins, C. E., Kleve, S., Leung, G. K. W., & Bonham, M. P. (2024). Conceptualizing weight management for night shift workers: A mixed-methods systematic review. Obesity Reviews, 25(2), e13659. https://doi.org/10.1111/obr.13659
Fleury, N., Geldenhuys, S., & Gorman, S. (2016). Sun Exposure and Its Effects on Human Health: Mechanisms through Which Sun Exposure Could Reduce the Risk of Developing Obesity and Cardiometabolic Dysfunction. International Journal of Environmental Research and Public Health, 13(10), 999. https://doi.org/10.3390/ijerph13100999
Hansen, M. S., Wölfel, E. M., Jeromdesella, S., Møller, J.-J. K., Ejersted, C., Jørgensen, N. R., Eastell, R., Hansen, S. G., & Frost, M. (2024). Once-weekly semaglutide versus placebo in adults with increased fracture risk: A randomised, double-blinded, two-centre, phase 2 trial. eClinicalMedicine, 72, 102624. https://doi.org/10.1016/j.eclinm.2024.102624
Hibberd, T. J., Ramsay, S., Spencer-Merris, P., Dinning, P. G., Zagorodnyuk, V. P., & Spencer, N. J. (2023). Circadian rhythms in colonic function. Frontiers in Physiology, 14. https://doi.org/10.3389/fphys.2023.1239278
Iacobucci, G. (2025). GLP-1 agonists: 82 deaths linked to adverse reactions, UK data show. BMJ, 388, r390. https://doi.org/10.1136/bmj.r390
Ju, H. Y., Song, S.-E., Shin, S.-K., Jeong, G.-S., Cho, H.-C., Im, S.-S., & Song, D.-K. (2025). Fulvic acid inhibits the differentiation of 3T3-L1 adipocytes by activating the Ca2+/CaMKⅡ/AMPK pathway. Biochemical and Biophysical Research Communications, 743, 151173. https://doi.org/10.1016/j.bbrc.2024.151173
Lopez-Minguez, J., Gómez-Abellán, P., & Garaulet, M. (2019). Timing of Breakfast, Lunch, and Dinner. Effects on Obesity and Metabolic Risk. Nutrients, 11(11), 2624. https://doi.org/10.3390/nu11112624
PA-C, J. F., MMSc. (2025, April 14). How does Ozempic work? Understanding GLP-1s for diabetes, weight loss, and beyond. Harvard Health. https://www.health.harvard.edu/staying-healthy/how-does-ozempic-work-understanding-glp-1s-for-diabetes-weight-loss-and-beyond
Porter, J. L., & Varacallo, M. A. (2025). Osteoporosis. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK441901/
Schlomann, B. H., & Parthasarathy, R. (2019). Timescales of gut microbiome dynamics. Current Opinion in Microbiology, 50, 56–63. https://doi.org/10.1016/j.mib.2019.09.011
Zecca, L., Casella, L., Albertini, A., Bellei, C., Zucca, F. A., Engelen, M., Zadlo, A., Szewczyk, G., Zareba, M., & Sarna, T. (2008). Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson’s disease. Journal of Neurochemistry, 106(4), 1866–1875. https://doi.org/10.1111/j.1471-4159.2008.05541.x
Share this post